Jack Allen
Stock Analyst at Robert W. Baird
(0.04)
# 4,710
Out of 4,988 analysts
334
Total ratings
28.5%
Success rate
-16.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jack Allen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLLS Cellectis | Reiterated: Buy | $10 → $8 | $1.53 | +422.88% | 27 | Sep 15, 2026 | |
| RARE Ultragenyx Pharmaceutical | Downgraded: Hold | $40 → $16 | $14.51 | +10.27% | 13 | Sep 3, 2026 | |
| TSHA Taysha Gene Therapies | Reiterated: Buy | $12 → $15 | $5.02 | +198.80% | 27 | Jun 30, 2026 | |
| FTH Faeth Therapeutics | Initiated Coverage: Buy | $57 | $34.50 | +65.22% | 1 | Jun 26, 2026 | |
| LYEL Lyell Immunopharma | Initiated Coverage: Buy | $49 | $11.01 | +345.05% | 1 | May 1, 2026 | |
| NTLA Intellia Therapeutics | Reiterated: Hold | $7 → $13 | $12.14 | +7.08% | 25 | Apr 27, 2026 | |
| ALLO Allogene Therapeutics | Reiterated: Buy | $7 → $9 | $1.69 | +432.54% | 23 | Apr 14, 2026 | |
| TIL Instil Bio | Downgraded: Hold | $180 → $7 | $7.09 | -1.27% | 28 | Jan 7, 2026 | |
| MREO Mereo BioPharma Group | Reiterated: Buy | $8 → $1 | $0.303 | +230.03% | 5 | Dec 29, 2025 | |
| VOR Vor Biopharma | Reiterated: Buy | $64 → $46 | $21.40 | +114.95% | 29 | Dec 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $52 → $44 | $56.56 | -22.21% | 13 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $1.03 | +385.44% | 20 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $6 | $2.70 | n/a | 9 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $3.09 | n/a | 27 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $5 → $4 | $2.53 | n/a | 11 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0007 | n/a | 14 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $12.05 | n/a | 17 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $84 | $32.00 | n/a | 9 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $72 → $65 | $63.94 | n/a | 9 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $27 | $10.54 | n/a | 17 | Nov 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $200 → $25 | $10.02 | n/a | 9 | Sep 26, 2023 |
Cellectis
Sep 15, 2026
Reiterated: Buy
Price Target: $10 → $8
Current: $1.53
Upside: +422.88%
Ultragenyx Pharmaceutical
Sep 3, 2026
Downgraded: Hold
Price Target: $40 → $16
Current: $14.51
Upside: +10.27%
Taysha Gene Therapies
Jun 30, 2026
Reiterated: Buy
Price Target: $12 → $15
Current: $5.02
Upside: +198.80%
Faeth Therapeutics
Jun 26, 2026
Initiated Coverage: Buy
Price Target: $57
Current: $34.50
Upside: +65.22%
Lyell Immunopharma
May 1, 2026
Initiated Coverage: Buy
Price Target: $49
Current: $11.01
Upside: +345.05%
Intellia Therapeutics
Apr 27, 2026
Reiterated: Hold
Price Target: $7 → $13
Current: $12.14
Upside: +7.08%
Allogene Therapeutics
Apr 14, 2026
Reiterated: Buy
Price Target: $7 → $9
Current: $1.69
Upside: +432.54%
Instil Bio
Jan 7, 2026
Downgraded: Hold
Price Target: $180 → $7
Current: $7.09
Upside: -1.27%
Mereo BioPharma Group
Dec 29, 2025
Reiterated: Buy
Price Target: $8 → $1
Current: $0.303
Upside: +230.03%
Vor Biopharma
Dec 23, 2025
Reiterated: Buy
Price Target: $64 → $46
Current: $21.40
Upside: +114.95%
Nov 11, 2025
Reiterated: Hold
Price Target: $52 → $44
Current: $56.56
Upside: -22.21%
Sep 23, 2025
Reiterated: Buy
Price Target: $5
Current: $1.03
Upside: +385.44%
Aug 13, 2025
Reiterated: Buy
Price Target: $10 → $6
Current: $2.70
Upside: n/a
Jul 17, 2025
Reiterated: Buy
Price Target: $18
Current: $3.09
Upside: n/a
May 14, 2025
Reiterated: Hold
Price Target: $5 → $4
Current: $2.53
Upside: n/a
May 12, 2025
Rated: Hold
Price Target: n/a
Current: $0.0007
Upside: n/a
May 12, 2025
Rated: Hold
Price Target: n/a
Current: $12.05
Upside: n/a
Nov 6, 2024
Reiterated: Buy
Price Target: $84
Current: $32.00
Upside: n/a
Oct 30, 2024
Reiterated: Hold
Price Target: $72 → $65
Current: $63.94
Upside: n/a
Nov 16, 2023
Reiterated: Hold
Price Target: $27
Current: $10.54
Upside: n/a
Sep 26, 2023
Downgraded: Hold
Price Target: $200 → $25
Current: $10.02
Upside: n/a